about
SerpinB3 upregulates the Cyclooxygenase-2 / β-Catenin positive loop in colorectal cancerBiomarker Signature Discovery from Mass Spectrometry Data.Multivariate analysis approach to the plasma protein profile of patients with advanced colorectal cancer.An investigation on the nature of the peptide at m/z 904, overexpressed in plasma of patients with colorectal cancer and familial adenomatous polyposis.The role of MYH gene in genetic predisposition to colorectal cancer: another piece of the puzzle.A Specific Mutational Signature Associated with DNA 8-Oxoguanine Persistence in MUTYH-defective Colorectal Cancer.APC I1307K mutations and forkhead box gene (FOXO1A): another piece of an interesting correlation.Multiplexed protein signal pathway mapping identifies patients with rectal cancer that responds to neoadjuvant treatment.Circulating miR-182 is a biomarker of colorectal adenocarcinoma progression.PKH26 staining defines distinct subsets of normal human colon epithelial cells at different maturation stages.Clinical predictive circulating peptides in rectal cancer patients treated with neoadjuvant chemoradiotherapy.Matrix-assisted laser desorption/ionization, nanostructure-assisted laser desorption/ionization and carbon nanohorns in the detection of antineoplastic drugs. 1. The cases of irinotecan, sunitinib and 6-alpha-hydroxy paclitaxel.Alterations of the Plasma Peptidome Profiling in Colorectal Cancer Progression.Neoadjuvant treatment for locally advanced rectal carcinoma.Peptide Patterns as Discriminating Biomarkers in Plasma of Patients With Familial Adenomatous Polyposis.Next-generation sequencing for genetic testing of familial colorectal cancer syndromes.Cross-validation of a mass spectrometric-based method for the therapeutic drug monitoring of irinotecan: implementation of matrix-assisted laser desorption/ionization mass spectrometry in pharmacokinetic measurements.Field-assisted paper spray mass spectrometry for the quantitative evaluation of imatinib levels in plasma.A functional biological network centered on XRCC3: a new possible marker of chemoradiotherapy resistance in rectal cancer patientsCirculating Cell-Free DNA in Dogs with Mammary Tumors: Short and Long Fragments and Integrity Index.An integrative approach for the identification of prognostic and predictive biomarkers in rectal cancerTelomerase is an independent prognostic marker of overall survival in patients with colorectal cancer.Long-term follow-up after endoscopic forceps biopsies for early stage duodenal carcinoid: case report and review of endoscopic treatments.Predictive role of microRNA-related genetic polymorphisms in the pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients.Pharmacogenetics Biomarkers and Their Specific Role in Neoadjuvant Chemoradiotherapy Treatments: An Exploratory Study on Rectal Cancer Patients.Serum miR-125b is a non-invasive predictive biomarker of the pre-operative chemoradiotherapy responsiveness in patients with rectal adenocarcinoma.miRNAs in colon and rectal cancer: A consensus for their true clinical value.Soft tissue sarcoma and the hereditary non-polyposis colorectal cancer (HNPCC) syndrome: formulation of an hypothesis.Predictive response biomarkers in rectal cancer neoadjuvant treatment.MicroRNAs as tools and effectors for patient treatment in gastrointestinal carcinogenesis.Gene and MicroRNA Expression Are Predictive of Tumor Response in Rectal Adenocarcinoma Patients Treated With Preoperative Chemoradiotherapy.Early-age-at-onset colorectal cancer and microsatellite instability as markers of hereditary nonpolyposis colorectal cancer.Enabling cytoplasmic delivery and organelle targeting by surface modification of nanocarriers.Mass spectrometry in the pharmacokinetic studies of anticancer natural products.Insulin promotes HER2 signaling activation during Barrett's Esophagus carcinogenesis.Extracellular Matrix and Colorectal Cancer: How Surrounding Microenvironment Affects Cancer Cell Behavior?NOTCH3 signaling regulates MUSASHI-1 expression in metastatic colorectal cancer cells.MUTYH c.933+3A>C, associated with a severely impaired gene expression, is the first Italian founder mutation in MUTYH-Associated Polyposis.Factors affecting the treatment of multiple colorectal adenomas.Glutathione S-transferase P1 Ile105Val polymorphism is associated with haematological toxicity in elderly rectal cancer patients receiving preoperative chemoradiotherapy.
P50
Q30842687-A153531D-EFD4-4FDA-B0CC-43F638F93DA3Q30992612-4025DD2E-54CC-4478-9D0D-943A204607AEQ33264154-EA00C0BE-9797-49C4-9F0A-BC6608A9648AQ33310718-0B26D9AD-B064-4DE2-B9A3-F8FE5E02C1B9Q33345609-954773BD-36CC-4D98-BABB-93BED005EFF6Q33817702-909DD3AA-491B-4BDC-907B-0ABD0A7DA365Q34105011-1B965F67-2ACF-4D87-A4E5-20E7D835009EQ34289736-504B7A72-A96C-4C64-B83E-7692B3B907ECQ34334326-BE721869-9981-440F-A9F2-FA1001672574Q34395666-A4818AA6-11BE-49E4-A4FF-528F1ACCF3B8Q35529674-60646CB7-5EF4-416E-8555-DC0B85693A37Q35612651-E94D71D6-EDE5-4CDF-9C54-FD42B7A40CA0Q35778619-CBACB1ED-0972-459F-A502-25AF84464C39Q35885328-B774E1A6-444E-423B-88B8-52808090D55AQ35899548-998E8FAA-3589-47BF-B48F-700DEEFDC5DEQ35986817-EEDD80CA-8D06-48C5-AAE3-FD2782605E19Q36033002-C712722D-595D-480C-B4B2-54B3B49A924FQ36203262-1AD3C5F8-6663-460C-9696-D1EE0248C1C8Q36211293-5FEA5767-D7DD-4C4F-A7BB-F8FF5A7C8028Q36247593-43A6BF7A-C9BF-40C1-AC8C-56FA35F3D9A7Q36544900-79558810-0CEE-43FD-8A82-251F440E3C39Q36594047-919E3244-8616-4B79-9FBA-39676F1E1088Q36794439-DC23CE8A-D3B7-489A-8685-B961773CDA47Q37190172-96A73A1B-9598-4FE6-AD4C-F0A6254F9672Q37286470-4094E05F-A82C-48ED-B136-C812F266F9D7Q37317631-3E2EE07C-CA59-43FF-B5A3-C4FFFA8A1CA5Q37746034-C6CC6204-8AEE-421A-9CE4-2A3A2C4498C5Q38025338-0798FA50-73BE-4B4A-9914-786D7FECC6BAQ38175761-CEEDFD75-5F7B-4316-9DF6-A2ED99653CB2Q38286304-D32A6730-F14D-48DC-B7E7-D8ACADA1CCB9Q38441043-49475102-BC78-42EB-AFC4-7DAA84D28F37Q38453105-75333A28-EDCC-44B8-BDFA-DBE0E2F8EE8CQ38542276-DA44292B-50DD-4828-8A06-98DBD3DEDD34Q38568180-E6C11032-FF93-44DD-8E14-8CFB1F0187A4Q38968119-3861AB89-2E5C-45C8-AB42-CB6A1425C080Q38989294-CE2B63A9-0532-4E0A-ACE3-503E68B1322BQ39024084-5D27DC54-8F5C-49BF-BCA2-00E98BCE5306Q39302047-24136829-38B1-4040-9DCE-F7CC04ADE47CQ43443989-353D4F0F-A73B-453A-8583-18F6F569F3CBQ43562922-5DAD1810-1027-406C-9AD9-9D785F4E3663
P50
description
hulumtues
@sq
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
Marco Agostini
@ast
Marco Agostini
@en
Marco Agostini
@es
Marco Agostini
@nl
Marco Agostini
@sl
type
label
Marco Agostini
@ast
Marco Agostini
@en
Marco Agostini
@es
Marco Agostini
@nl
Marco Agostini
@sl
prefLabel
Marco Agostini
@ast
Marco Agostini
@en
Marco Agostini
@es
Marco Agostini
@nl
Marco Agostini
@sl
P108
P214
P106
P1153
7005322173
P21
P214
P31
P396
IT\ICCU\CFIV\274156
P496
0000-0001-7578-1233
P569
1973-01-01T00:00:00Z
P734
P735
P7859
viaf-307344752